A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer
作者： Ramesh K. Ramanathan , Joel Picus , Haralambos Raftopoulos , Stephen Bernard , A. Craig Lockhart
DOI: 10.1007/S00280-007-0489-5
关键词:
摘要: Background Milataxel is a novel taxane analog, with evidence of enhanced preclinical activity compared to paclitaxel and docetaxel, especially in cell lines that over express P-glycoprotein. Based on data milataxel may be active colorectal cancer (CRC), phase II study was performed patients advanced previously treated CRC.
springer.com
elsevier.com
sci-hub.se 参考文章(22)
Theodora Voskoglou-Nomikos, Lesley Seymour, Joseph L. Pater, Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models Clinical Cancer Research. ,vol. 9, pp. 4227- 4239 ,(2003)
Carolyn M Discafani, Frank Loganzo, Tami Annable, Sylvia Musto, Patricia Gallagher, Xingzhi Tan, Deepak Sampath, Hao Liu, Carl Beyer, Lee M Greenberger, Carol Rios, MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Molecular Cancer Therapeutics. ,vol. 2, pp. 873- 884 ,(2003)
A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal, M. J. Thun, Cancer statistics, 2006. CA: A Cancer Journal for Clinicians. ,vol. 56, pp. 106- 130 ,(2006) , 10.3322/CANJCLIN.56.2.106
Tara Beers Gibson, Aarati Ranganathan, Axel Grothey, Randomized Phase III Trial Results of Panitumumab, a Fully Human Anti—Epidermal Growth Factor Receptor Monoclonal Antibody, in Metastatic Colorectal Cancer Clinical Colorectal Cancer. ,vol. 6, pp. 29- 31 ,(2006) , 10.3816/CCC.2006.N.01
Charles Erlichman, Daniel J. Sargent, New Treatment Options for Colorectal Cancer The New England Journal of Medicine. ,vol. 351, pp. 391- 392 ,(2004) , 10.1056/NEJME048151
A. Sparreboom, J. van Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. F. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, O. van Tellingen, Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proceedings of the National Academy of Sciences of the United States of America. ,vol. 94, pp. 2031- 2035 ,(1997) , 10.1073/PNAS.94.5.2031
J I Johnson, S Decker, D Zaharevitz, L V Rubinstein, J M Venditti, S Schepartz, S Kalyandrug, M Christian, S Arbuck, M Hollingshead, E A Sausville, Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British Journal of Cancer. ,vol. 84, pp. 1424- 1431 ,(2001) , 10.1054/BJOC.2001.1796
A. C. Lockhart, R. Bukowski, M. L. Rothenberg, K. K. Wang, W. Cooper, J. Grover, L. Appleman, P. R. Mayer, M. Shapiro, A. X. Zhu, Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. Cancer Chemotherapy and Pharmacology. ,vol. 60, pp. 203- 209 ,(2007) , 10.1007/S00280-006-0362-Y
Michael M. Gottesman, Tito Fojo, Susan E. Bates, Multidrug resistance in cancer: role of ATP–dependent transporters Nature Reviews Cancer. ,vol. 2, pp. 48- 58 ,(2002) , 10.1038/NRC706
Richard Simon, Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials. ,vol. 10, pp. 1- 10 ,(1989) , 10.1016/0197-2456(89)90015-9